Marie-Odile Roy

USPTO Granted Patents = 10 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 4)

Average Co-Inventor Count = 4.5

ph-index = 2

Forward Citations = 26(Granted Patents)

Location History:

Brussels, BE (2010)
Brussels, BG (2013)
Paris, FR (2014 - 2021)

Company Filing History:

The Scripps Research Institute

patents

where one patent can have more than one assignee

Years Active: 2010-2021

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10941151 - Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof (2021-03-09),

2. 10683295 - Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof (2020-06-16),

3. 10544150 - NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders (2020-01-28),

4. 10065961 - Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof (2018-09-04),

5. 10065960 - NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders (2018-09-04),

6. 9926325 - NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders (2018-03-27),

7. 9475814 - [object Object] (2016-10-25),

8. 8871761 - NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders (2014-10-28),

9. 8497075 - Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligands (2013-07-30),

10. 7824866 - Ligand for G-protein coupled receptor GPR72 and uses thereof (2010-11-02),

Title: Celebrating the Innovations of Inventor Marie-Odile Roy

Introduction

Marie-Odile Roy is a prominent inventor based in Paris, France, known for her significant contributions to the field of pharmaceuticals. With an impressive portfolio of ten patents, she has developed innovative solutions that have the potential to make a meaningful impact on therapeutic treatments.

Latest Patents

Among her latest patents, Marie-Odile has focused on chiral compounds, specifically the "Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists." This invention pertains to novel compounds and their applications in treating NK-3 receptor mediated disorders. It emphasizes a novel chiral synthesis method using N-sp3 protective groups and provides important intermediates that facilitate the creation of these compounds.

Career Highlights

Marie-Odile Roy’s career has been marked by her employment at innovative companies such as Ogeda SA and Euroscreen SA. Her work with these firms underscores her role in advancing pharmaceutical chemistry and her commitment to improving healthcare outcomes through her research.

Collaborations

Throughout her career, Marie-Odile has collaborated with noteworthy individuals in her field, including Hamid R. Hoveyda and Graeme Lovat Fraser. These collaborations have allowed her to enrich her research and further develop her innovative ideas into practical applications.

Conclusion

Marie-Odile Roy exemplifies the spirit of innovation with her extensive body of work and impactful patents. Her dedication to developing new therapeutic inventions is inspiring, showcasing the potential of chiral compounds in modern medicine. As she continues to pioneer advancements in pharmaceuticals, her contributions will undoubtedly leave a lasting legacy in the field.

This text is generated by artificial intelligence and may not be accurate.